Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19

Abstract

The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir-ritonavir and those who received placebo. (Supported by Pfizer; EPIC-SR ClinicalTrials.gov number, NCT05011513.).

References

Page 1

	Year	Citations
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Zunyou Wu, Jennifer M. McGoogan JAMA Virus EpidemiologyDisease OutbreakCovid-19 EpidemiologyCovid-19Clinical Epidemiology	2020	17.8K
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study Annemarie B Docherty, Ewen M. Harrison, Christopher Green, BMJ	2020	3.6K
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 New England Journal of Medicine	2022	2.1K
An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19 Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson, Science Viral DiagnosticsWorldwide OutbreakImmunologyImmunotherapeuticsCovid-19 Epidemiology	2021	1.8K
Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET) Lindsay Kim, Shikha Garg, Alissa O’Halloran, Clinical Infectious Diseases	2020	667
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge Ronen Arbel, Yael Wolff Sagy, Moshe Hoshen, New England Journal of Medicine	2022	354
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, The Lancet Omicron WaveReal-world EffectivenessHealthcare-associated InfectionHong KongAntiviral Therapy	2022	286
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system Joseph A. Lewnard, John M. McLaughlin, Vennis Hong, The Lancet Infectious Diseases	2023	125
Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes Kristina L. Bajema, Kristin Berry, Elani Streja, Annals of Internal Medicine	2023	91
Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19 Kevin L. Schwartz, Jun Wang, Mina Tadrous, Canadian Medical Association Journal	2023	90

Page 1